Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel

Observational Study on Perception of Information and Quality of Life in Neuroendocrine Tumor on Lanreotide Autogel

The purpose of the study is to evaluate, in standard practice, the change in information received and perceived by the patient, extension of the disease and its treatment. These parameters will be evaluated by means of validated self-administered questionnaires that can be used in standard practice.

Inclusion Criteria:

• Gastroenteropancreatic neuroendocrine tumor (GEPNET), histologically proven, grade

  1 or 2,

• Subject eligible for antitumor treatment initiation with lanreotide autogel*, alone or combined with other therapies, selected freely and prior to inclusion in the study by the physician,

• Subject able to complete a self-administered evaluation questionnaire during initiation visit and liable to be seen again within 6 months of the initial visit based on the physician's usual practices

• Having consented in writing to his/her data being accessed for participation in the study.

Exclusion Criteria:

• Previously treated by lanreotide autogel
• Simultaneously participating in a clinical trial